2-Methoxyestrone + 2-Methoxyestradiol [2-MeO(E1+E2)]

Your body does not just make estrogen. It also breaks it down, and the path it takes matters. Two of the gentler end products of that breakdown are 2-MeO-E1 (2-methoxyestrone) and 2-MeO-E2 (2-methoxyestradiol). When these show up in your urine in healthy amounts, it suggests your body is steering estrogen down a route that has been linked in research to lower breast cancer risk and healthier blood vessels in pregnancy.

This is a research-grade marker, not a routine number with strict cutoffs. But for someone paying attention to hormone health, family history of breast or prostate cancer, or pregnancy complications, it offers a window your standard estrogen panel does not. Think of it less as a single verdict and more as a trail marker you can follow over time.

What This Test Actually Measures

Your liver, kidneys, brain, placenta, uterus, and breast tissue all carry an enzyme called COMT (catechol-O-methyltransferase). COMT takes a reactive form of estrogen called 2-hydroxyestrogen and caps it with a small chemical tag (a methoxy group), turning it into 2-MeO-E1 or 2-MeO-E2. That cap quiets estrogen's signal and makes the molecule easier for your body to send out in urine.

This test adds those two methylated metabolites together to give you a single number representing how active that protective methylation step is for you. Because it is a 24-hour urine collection, it captures what your body produced and cleared over a full day, not just a single moment.

Breast Cancer Risk

This is where the evidence base for 2-MeO(E1+E2) is strongest. In a nested case-control study of postmenopausal women, those whose estrogen flowed more heavily through the 2-pathway, including higher 2-MeO-E2, had lower breast cancer risk (with odds ratios around 0.53 for 2-methoxyestradiol comparing highest to lowest quartile). The more robust replicated finding across cohorts is that a higher ratio of 2-hydroxylation pathway metabolites relative to parent estrogens is protective, rather than absolute levels of any single 2-MeO metabolite on its own.

The takeaway for you: a higher fraction of your estrogen ending up as 2-MeO(E1+E2), relative to your parent estrogens, appears to be a sign that your body is favoring its safer cleanup route. This does not guarantee anything about individual risk, but it gives you a measurable hormonal trait to track alongside more established markers.

Prostate Cancer

In men, the story is more nuanced and runs in the opposite direction. In a study of 527 men with localized prostate cancer treated surgically, higher urinary 2-MeO-E1 was linked to greater risk of metastasis or death afterward. So in this setting, more 2-MeO-E1 in urine flagged a worse prognosis, not a better one.

What this means: 2-MeO(E1+E2) is not a universal good number or bad number. The same metabolite can signal different things in different bodies and different diseases. For men with a personal or family history of prostate cancer, this finding is worth noting and worth discussing alongside PSA (prostate-specific antigen) and other workup.

Reconciling These Opposite Signals

It is fair to ask: how can higher 2-MeO levels look protective in postmenopausal breast cancer and harmful in prostate cancer? The answer is that this is not a good or bad number on its own. It is a phenotype indicator, a window into how your hormone metabolism is running. The same shift in metabolism that may quiet estrogen-driven breast tissue may also reflect a hormonal environment that behaves differently in prostate tissue. The marker tells you about your pattern; the meaning of the pattern depends on the tissue and the question you are asking.

Colorectal Cancer in Men

A study examining sex hormones and colorectal cancer found that plasma 2-MeO-E1 was higher in men with colorectal cancer, and the marker discriminated well between affected and unaffected men, with an AUC (area under the curve, a measure where 1.0 is perfect and 0.5 is random) of 0.88. A genetic variant in COMT also altered risk through this same pathway. This is a single study and the marker is not in routine colorectal cancer screening, but it adds another reason to take an unexpected reading seriously.

Pregnancy and Preeclampsia

During a normal pregnancy, 2-MeO-E2 rises steadily and 2-MeO-E1 peaks mid-pregnancy. In women who develop preeclampsia, the high-blood-pressure pregnancy complication, 2-MeO-E2 drops in both mild and severe disease, and 2-MeO-E1 drops further in severe disease. Lower 2-methoxyestradiol has also been tied to higher blood pressure, more proteinuria, and worse angiogenic balance during pregnancy.

If you are pregnant or planning a pregnancy, particularly with a history of preeclampsia or hypertension, this marker is one of the few that connects directly to the vascular biology of the placenta. It is not yet a screening test in pregnancy guidelines, but the consistency of the human findings is striking.

Endometriosis and Treatment-Resistant Depression

In a study of 340 women, those with ovarian endometriosis specifically showed enhanced 2-hydroxylation, with higher 2-MeO-E1 and 2-OH-E1 levels compared to controls. Pain symptoms within that group tracked most clearly with 2-OH-3MeO-E1 rather than with 2-MeO-E1 or 2-MeO-E2 directly. Separately, women with treatment-resistant depression have shown reduced 2-MeO-E2 alongside increased markers of cellular stress, suggesting disturbed estrogen metabolism may play a role.

These are smaller research findings, not screening indications. But they hint at why hormone metabolism may matter in conditions that are not usually thought of as hormonal.

Why One Reading Is Not Enough

A 24-hour urine reading is a snapshot of your hormone metabolism on one particular day. Estrogen output varies across the menstrual cycle in premenopausal women, shifts during pregnancy, and responds to BMI changes, supplements, contraceptives, and stress. Because there are no standardized clinical cutoffs for 2-MeO(E1+E2), a single value is hard to interpret on its own. A trend over time, especially before and after a change you are making, is much more informative.

A practical cadence: get a baseline, then retest in 3 to 6 months if you are making meaningful changes (starting or stopping hormone therapy, beginning a supplement like DIM (3,3'-diindolylmethane), losing or gaining significant weight, or addressing a pregnancy concern). After that, annual monitoring is reasonable for anyone using this as part of a longer hormonal-health picture.

When Results Can Be Misleading

A 24-hour urine test is only as accurate as the collection. The most common reason results are off is incomplete collection, missing the first morning void or a daytime trip to the bathroom. Several biological and lifestyle factors also distort what a single reading reflects:

• Body weight: higher BMI is associated with lower methylation of estrogen metabolites, which can push 2-MeO(E1+E2) down even when the underlying biology is otherwise healthy.
• Oral contraceptives: combined pills containing ethinyl estradiol and drospirenone increase hydroxylation and methylation of endogenous estrogen, raising 2-MeO output.
• DIM and indole-3-carbinol supplements: widely used cruciferous-vegetable concentrates that shift the urinary estrogen profile, including the 2-MeO-E1 to 2-OH-E1 balance.
• Genetic variants in COMT or CYP3A7: can change baseline 2-methylation activity, meaning your number reflects your inherited pattern, not a fixable problem.

What an Unexpected Result Should Lead You to Do

Because this is a research-grade marker, a single out-of-pattern result should not drive a big decision on its own. The most useful next steps are pattern-based:

• Look at the rest of your estrogen profile: parent estrogens (estrone, estradiol, estriol), the 2-hydroxy and 4-hydroxy metabolites, and the 2-OH to 16-OH ratio give context that a single 2-MeO number cannot.
• Consider your hormonal state: menstrual cycle day, menopause status, contraceptive use, and pregnancy all reshape the meaning of the number.
• Repeat the collection: a second 24-hour urine done carefully can resolve whether the original result reflected real biology or a collection issue.
• Loop in the right specialist: a gynecologist for unexplained menstrual or pregnancy issues, a breast specialist or oncologist if you have a personal or family history of breast cancer, or a urologist for men with prostate cancer history.

This marker is most powerful when read alongside a fuller picture of your hormone metabolism, not as a stand-alone verdict.